drugset / Trial / NCT02537444
Acalabrutinib (ACP-196) Alone and in Combination With Pembrolizumab in Ovarian Cancer (KEYNOTE191)
RandomizedSingle-groupOpen-labelTreatment
Summary
To characterize the safety and efficacy of acalabrutinib (ACP-196) monotherapy and acalabrutinib plus pembrolizumab combination therapy in subjects with recurrent ovarian cancer
Timeline
- Start
- 2015-11
- Primary completion
- 2018-07
- Completion
- 2018-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acalabrutinib | Small molecule | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |